Antiproteinuric Response to Finerenone in Diabetic Kidney Disease: Responder and Non-Responder Subgroup Analysis of the FINDKDLATAM Study

Background/Objectives: Albuminuria is an early marker of kidney damage and an independent predictor of adverse outcomes, making its reduction a key therapeutic goal. Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has demonstrated renal and cardiovascular benefits in patients with diabetic kidney disease (DKD), although the magnitude of the antiproteinuric response may vary in clinical practice. This post hoc analysis aimed to characterize the six-month antiproteinuric response to finerenone and to descriptively explore baseline clinical and treatment characteristics across response categories in the FINDKDLATAM cohort.